- Home
- CHH vs SLNO Comparison
CHH vs SLNO Comparison
Compare CHH & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHH
- SLNO
- Stock Information
- Founded
- CHH 1939
- SLNO 1999
- Country
- CHH United States
- SLNO United States
- Employees
- CHH N/A
- SLNO N/A
- Industry
- CHH Hotels/Resorts
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CHH Consumer Discretionary
- SLNO Health Care
- Exchange
- CHH Nasdaq
- SLNO Nasdaq
- Market Cap
- CHH 4.6B
- SLNO 3.8B
- IPO Year
- CHH 1997
- SLNO 2014
- Fundamental
- Price
- CHH $97.08
- SLNO $64.20
- Analyst Decision
- CHH Hold
- SLNO Strong Buy
- Analyst Count
- CHH 15
- SLNO 9
- Target Price
- CHH $133.27
- SLNO $116.78
- AVG Volume (30 Days)
- CHH 494.3K
- SLNO 1.4M
- Earning Date
- CHH 11-05-2025
- SLNO 11-04-2025
- Dividend Yield
- CHH 1.18%
- SLNO N/A
- EPS Growth
- CHH 34.90
- SLNO N/A
- EPS
- CHH 6.50
- SLNO N/A
- Revenue
- CHH $797,866,000.00
- SLNO $32,656,999.00
- Revenue This Year
- CHH $99.70
- SLNO N/A
- Revenue Next Year
- CHH $3.67
- SLNO $182.29
- P/E Ratio
- CHH $14.97
- SLNO N/A
- Revenue Growth
- CHH N/A
- SLNO N/A
- 52 Week Low
- CHH $96.88
- SLNO $41.50
- 52 Week High
- CHH $157.86
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- CHH 33.28
- SLNO 48.91
- Support Level
- CHH $98.21
- SLNO $64.30
- Resistance Level
- CHH $105.15
- SLNO $67.93
- Average True Range (ATR)
- CHH 2.79
- SLNO 3.52
- MACD
- CHH 0.27
- SLNO 0.33
- Stochastic Oscillator
- CHH 1.69
- SLNO 34.24
About CHH Choice Hotels International Inc.
As of Dec. 31, 2024, Choice Hotels operated 654,000 rooms across the economy, midscale, upscale, and extended-stay segments. Comfort Inn and Comfort Suites are the largest brands (26% of the company's total domestic rooms), while Ascend and Cambria (10% of total domestic rooms) are newer lifestyle and select-service brands. Choice closed on its Radisson acquisition in August 2022, which added about 70,000 rooms. Franchises account for 100% of total revenue, and the United States represented 78% of total rooms in 2024.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.